5 Stocks in the News…
Things like news releases or earnings announcements can be important triggers to look for… And we found 5 stocks that appear to be in an excellent position to deliver high-probability trading opportunities in the days and weeks ahead.

Click Here to Get ALL 5 Stocks.
Carrie C. Strom net worth and biography

Carrie Strom Biography and Net Worth

SVP of AbbVie
Carrie Strom is Senior Vice President, AbbVie, and President, Global Allergan Aesthetics and has served in this role since May 2020.  Prior to joining AbbVie, Ms. Strom served as Senior Vice President of U.S. Medical Aesthetics at Allergan® beginning in May 2018, overseeing the aesthetic portfolio for the multi-billion dollar U.S. business.  Previously, Ms. Strom was Vice President of Marketing, Plastic Surgery and Regenerative Medicine at Allergan and she was instrumental in the $2.8B acquisition and integration of LifeCell.  Before Allergan, Ms. Strom spent over 10 years at Pfizer where she led marketing for a leading statin and held various other sales and marketing roles.  Ms. Strom received a B.A. in Communications from the University of Colorado, Boulder. She is an advocate for women in business and is actively involved with the Girls Inc. organization. She serves on the board of directors for Octane in Southern California and is a member of the Komen Leadership Council in Orange County. At AbbVie, she is the executive chair of the PRIDE Employee Resource Group.

What is Carrie C. Strom's net worth?

The estimated net worth of Carrie C. Strom is at least $10.38 million as of May 3rd, 2021. Ms. Strom owns 63,409 shares of AbbVie stock worth more than $10,377,517 as of December 3rd. This net worth approximation does not reflect any other investments that Ms. Strom may own. Learn More about Carrie C. Strom's net worth.

How do I contact Carrie C. Strom?

The corporate mailing address for Ms. Strom and other AbbVie executives is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. AbbVie can also be reached via phone at (847) 932-7900. Learn More on Carrie C. Strom's contact information.

Has Carrie C. Strom been buying or selling shares of AbbVie?

Carrie C. Strom has not been actively trading shares of AbbVie over the course of the past ninety days. Most recently, Carrie C. Strom sold 2,396 shares of the business's stock in a transaction on Monday, February 7th. The shares were sold at an average price of $141.17, for a transaction totalling $338,243.32. Learn More on Carrie C. Strom's trading history.

Who are AbbVie's active insiders?

AbbVie's insider roster includes Carlos Alban (Vice Chairman), Roxanne Austin (Director), Nicholas Donoghoe (SVP), Brian Durkin (VP), Richard Gonzalez (CEO), Henry Gosebruch (EVP), Robert Michael (Vice Chairman), Scott Reents (Sr. VP & CFO ), Timothy Richmond (EVP), Azita Saleki-Gerhardt (EVP), Laura Schumacher (Vice Chairman), Michael Severino (Vice Chairman), Elaine Sorg (SVP), Jeffrey Stewart (EVP), and Carrie Strom (SVP). Learn More on AbbVie's active insiders.

Are insiders buying or selling shares of AbbVie?

During the last year, insiders at the sold shares 16 times. They sold a total of 997,100 shares worth more than $140,525,236.75. The most recent insider tranaction occured on May, 23rd when Vice Chairman Michael Severino sold 79,801 shares worth more than $12,041,970.90. Insiders at AbbVie own 0.1 % of the company. Learn More about insider trades at AbbVie.

Information on this page was last updated on 5/23/2022.

Carrie C. Strom Insider Trading History at AbbVie

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/7/2022Sell2,396$141.17$338,243.32View SEC Filing Icon  
8/23/2021Sell5,057$120.00$606,840.0011,595View SEC Filing Icon  
5/3/2021Sell4,184$112.40$470,281.6063,409View SEC Filing Icon  
See Full Table

Carrie C. Strom Buying and Selling Activity at AbbVie

This chart shows Carrie C Strom's buying and selling at AbbVie by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

AbbVie Company Overview

AbbVie logo
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Read More

Today's Range

Now: $163.66
Low: $160.51
High: $163.76

50 Day Range

MA: $148.46
Low: $134.21
High: $163.66

2 Week Range

Now: $163.66
Low: $117.00
High: $175.91


4,252,299 shs

Average Volume

6,597,847 shs

Market Capitalization

$289.43 billion

P/E Ratio


Dividend Yield



5 Stocks in the News…
Things like news releases or earnings announcements can be important triggers to look for… And we found 5 stocks that appear to be in an excellent position to deliver high-probability trading opportunities in the days and weeks ahead.

Click Here to Get ALL 5 Stocks.